Table 1

Demographics and clinical characteristics of the study patients who attended at both end points

CharacteristicsBaseline(n = 54)Follow-up(n = 34)p Value (Wilcoxon signed-rank test)
Age (years), mean (range)30.6 (16–48)
Male sex (%)62
Disease duration (weeks), median (range)24 (2–260)
Early morning stiffness (min), median (IQR) (range 0–120)60 (2–180)30 (0–120)0.001
Patients receiving NSAIDs (%)8256
Patients receiving DMARDs (%)0.017.6
VAS back pain during day (mm), median (IQR) (range 0–100)50 (34–70)18 (5–61)0.004
VAS back pain during night (mm), median (IQR) (range 0–100)57 (20–77)20 (6–66)0.012
BASFI, median (IQR) (range 0–10)3.98 (2.43–6.35)1.45 (0.00–3.40)0.008
BASDAI, median (IQR) (range 0–10)5.65 (3.28–7.53)3.05 (0.82–5.23)0.009
ASQoL, median (IQR) (range 0–18)9 (6–12)5 (0–10)0.001
HLA-B27 positive (%)5455.8
C-reactive protein (mg/l), median (range)8 (<5–65)6 (<5–42)0.003
Peripheral synovitis (%)232.9
History of IBD (%)0
History of psoriasis (%)12.5
History of alternate buttock pain (%)61
Enthesopathy (%)48
Positive family history (%)29
ESSG diagnosis (number of patients)
    Psoriatic spondylitis31
    Reactive arthritis62
    Ankylosing spondylitis08
    Undifferentiated spondyloarthropathy4120
  • ASQoL, ankylosing spondylitis quality of life; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; DMARDs, disease-modifying antirheumatic drugs; ESSG, European Spondyloarthropathy Study Group; IBD, inflammatory bowel disease; IQR, interquartile range; NSAIDs, non-steroidal anti-inflammatory drugs; VAS, visual analogue scale.